MEDICO35.00

Medico Remedies Limited

· Pharma & Health
₹ CrorePeersMEDICAMEQHALEOSLABSAAREYDRUGSNECLIFEALBERTDAVDVALIANTLABNATCAPSUQZIMLABMcap ₹0.1 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth+4.2+36.7
EBITDA Growth+16.2+13.5
EBIT Growth+19.4+16.4
Net Income Growth+21.7+29.9
EPS Growth+22.0+29.5
Total Assets Growth+24.4+28.2
Total Equity Growth+18.9+21.2
Cash from Operations Growth+100.7+20.1
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.